PACS Group Q3 2026 Earning Call - PACS GROUP INC

Explicit Guidance:

• Full-Year 2026 Revenue: Increased to a range of $5.95 billion to $6.05 billion (midpoint represents ~13% growth vs. 2025).
• Full-Year 2026 Adjusted EBITDA: Increased to a range of $685 million to $695 million (midpoint represents ~37% growth vs. 2025).
• 2026 Growth Drivers: The updated guidance incorporates contributions from the 32 Florida facilities (acquired Oct 1) and 11 Texas facilities (acquired Nov 1) for the partial year of operation, plus a $5 million one-time EBITDA contribution from retroactive quality incentive payments received in Ohio in October.
• 2027 Outlook: No formal guidance provided; management expects continued strong performance, noting an expected $1+ million WQIP payment from California in Q1 2027 (timing based on 2025 payment cycle) and higher base rates in Ohio following the incorporation of one-time quality payments into state rates.
• Cash Flow: Expected to continue generating strong operating cash flow, supporting M&A and facility investments.

Business-Segment Outlook:

• Organic Growth: Anticipated continued mid-single-digit top-line growth driven by increasing occupancy and skilled mix in same-store (mature) facilities, which are currently at ~93% occupancy and 31.3% skilled mix.
• Acquisition Integration (Aduro, Florida, Texas): Expect a "substantial initial lift" required to establish clinical systems and leadership, involving significant near-term integration investments that will precede operating improvements.
• Performance Targets: Goal to advance newly acquired facilities toward the 100% occupancy and 100% skilled mix levels seen in select mature communities, with a proven track record of converting the gap between new and mature cohorts (currently ~17 points in occupancy, ~10 points in skilled mix) into value over time.
• Ramp Timeline: Facilities are expected to hit the "ramping" phase performance trajectory after approximately 18 months of ownership.

Market and Competitive Outlook:

• Labor Environment: Described as the "best" in years; agency staffing costs are trending down, and management is "ahead of schedule" in eliminating premium labor costs in new markets.
• Talent Acquisition: Strong ability to attract talent to skilled nursing (skilled labor, administrators), particularly in Florida and Texas, supported by state-specific tuition reimbursement programs.
• M&A Pipeline: Described as an "influx of deals," with a higher volume of opportunities than historically seen. Management remains disciplined, focusing on moderately performing or underperforming distressed facilities.
• Market Expansion: Florida and Texas now serve as regional hubs, creating a "tuck-in" effect that attracts new deal flow in those specific states.
• Quality & Reimbursement: Payers are increasingly linking reimbursement to quality outcomes; states like Texas, Florida, Ohio, and Tennessee are embedding quality incentives directly into rates.

Macro / Industry Outlook:

• Political/Regulatory Landscape: While anticipating potential increased regulatory scrutiny under a Democratic Congress (e.g., minimum staffing mandates), management views this as "normal operating" for the sector.
• Payer Rates: Anticipates a positive "silver lining" from political shifts where Democrats traditionally better fund entitlement programs (Medicaid/Medicare), potentially leading to improved rate growth.
• Florida Market: Specific market dynamics noted as improved compared to years ago, with higher state-average occupancy and skilled mix, and a more favorable reimbursement landscape.
• Demographics: Cites "serious tailwinds" from demographic trends across the country supporting long-term demand for post-acute care.

Strategic Initiatives:

• Real Estate Strategy: Continues opportunistic purchases of underlying real estate (6 properties added in Q3) based on highest and best use of capital, without a fixed target for owned vs. rented mix.
• Leadership Development: Expanding the "Administrator in Training" (AIT) program (currently 54 trainees) to support leadership pipelines for new and existing facilities.
• Acquisitions: Completed acquisitions of 32 Florida facilities (4,049 beds) and 11 Texas facilities (10 SNF, 1 AL); actively evaluating a robust pipeline of transactions meeting strategic criteria.
• Remediation: Expected to complete internal control material weakness remediation and formally conclude effectiveness testing by end of 2026.
• Quality Initiatives: Continued focus on improving CMS star ratings, targeting 4-5 star ratings, with specific success in graduating facilities from Special Focus Facility (SFF) designation.

Risks and Headwinds to Outlook:

• Integration Costs: Near-term EBITDA will face pressure from investment-heavy integration costs for newly acquired Florida and Texas facilities before operational improvements materialize.
• Regulatory Uncertainty: Ongoing government investigations remain open; timing and ultimate outcome are unpredictable, though management maintains confidence in the resolution process.
• Acquisition Volatility: Not all incoming deals meet underwriting criteria; the firm may face pressure to grow but will prioritize disciplined underwriting over growth for growth's sake.
• Guidance Assumptions: Guidance assumes continued strength in existing operations to fund integration; any deterioration in same-store performance could impact the ability to absorb new facility costs.

Management Tone on the Future:

• Confidence: Highly confident in the "sustainability of the operating model" and the ability to turn around distressed assets.
• Discipline: Emphasizes "professionalized" underwriting and a refusal to overpay, despite a high volume of deals.
• Optimism: Views the labor market improvement and demographic tailwinds as structural advantages; describes the current state of affairs as a "position of strength" despite regulatory scrutiny.
• Hedging: Notes that guidance excludes non-recurring WQIP/quality payments (e.g., Ohio) and that future guidance will only include known payments by the time of release.

Miscellaneous:

• Liquidity: Ended Q3 2026 with $707.4 million in liquidity ($115.3 million cash); net leverage of 0.2x.
• Share Buybacks: Retained authorization to repurchase up to $250 million of shares, to be executed opportunistically.
• Financial Metrics: Reported adjusted net income of $104 million for Q3 2026; diluted EPS of $0.37.
• Non-GAAP: Management highlighted the exclusion of stock-based compensation and GAAP rent adjustments in EBITDA calculations.